Atrial flutter and fibrillation in patients with pulmonary hypertension
Introduction
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are diseases characterized by an obliterative pulmonary vasculopathy and a progressive increase in pulmonary vascular resistance eventually leading to right heart failure and death, if not effectively treated [1], [2]. Despite therapeutic advances, PAH remains an incurable disease. The same is true for CTEPH, at least for those patients who cannot undergo pulmonary endarterectomy surgery [3], [4]. With the introduction of active medical therapies, however, patients with PAH and inoperable CTEPH now have a better life expectancy than in earlier years [5], [6], [7], but most of them live with chronic right ventricular dysfunction.
The right ventricle has a variable capacity to adapt to an increased afterload but progressive pulmonary vasculopathy invariably results in cardiac remodeling. Elevated right-sided filling pressures and structural changes, primarily dilatation of the right atrium and right ventricle with subsequent tricuspid regurgitation may trigger atrial fibrillation and atrial flutter [8], [9], [10]. Case reports and observational studies suggest that these arrhythmias may have profound implications including a high risk of clinical deterioration, right heart failure, and death [8], [10], [11]. To the best of our knowledge, the incidence and clinical consequences of atrial flutter and fibrillation in patients with pulmonary hypertension have not been systematically evaluated and no studies have assessed the management of these arrhythmias in this patient population.
In order to further evaluate the incidence and clinical impact of new-onset atrial flutter and fibrillation in patients with chronic pulmonary hypertension, we conducted a prospective study of patients with PAH or inoperable CTEPH focusing on incidence, risk factors, clinical consequences, treatment patterns and survival.
Section snippets
Methods
This study enrolled all consecutive patients ≥ 18 years treated for PAH or inoperable CTEPH between January 2005 and December 2010. The follow-up was completed June 30th, 2011. To be eligible, patients had to have a complete diagnostic work-up according to contemporary standards [12], [13] including right heart catheterization demonstrating precapillary pulmonary hypertension with a mean pulmonary artery pressure (PAPm) ≥ 25 mm Hg and a pulmonary arterial occlusion pressure (PAOP) ≤ 15 mm Hg. For
Results
A total of 239 patients were enrolled; 157 with PAH and 82 with inoperable CTEPH. Forty-eight (20%) patients had at least one episode of atrial flutter or atrial fibrillation. Both types of arrhythmia were equally common (24 episodes each). Of the 24 cases of atrial flutter, 9 (37.5%) had a typical and 15 (62.5%) an atypical ECG pattern. Table 1 shows the baseline characteristics of the overall patient population and a comparison of the baseline characteristics of patients who did and did not
Discussion
The main findings of the present study are (i) the relatively high incidence of new-onset atrial flutter or fibrillation in patients with advanced pulmonary hypertension; (ii) the fact that the majority of these episodes were associated with marked clinical deterioration and signs of right heart failure; (iii) the observation that sinus rhythm could be successfully restored in the majority of patients resulting in clinical recovery; and (iv) the finding that the development of permanent atrial
Author contributions
Dr. Olsson: contributed to study design, collection, analysis and interpretation of data, drafting and critical review of the manuscript; and has seen and approved the final version.
Dr. Nickel: contributed to analysis and interpretation of data, critical review of the manuscript; and has seen and approved the final version.
Dr. Tongers: contributed to analysis and interpretation of data, critical review of the manuscript; and has seen and approved the final version.
Dr. Hoeper: contributed to
Disclosures
KMO has received speaker fees from Actelion and Pfizer; MMH has received fees for consultations and/or speaking at conferences from Actelion, Bayer, Gilead, GSK, Lilly, Novartis and Pfizer. The other authors have no conflicts of interest.
Funding
None.
Acknowledgement
The authors of this manuscript have certified that they comply with the principles of Ethical Publishing in the International Journal of Cardiology.
References (23)
- et al.
Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension
Am Heart J
(2007) - et al.
Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension
Int J Cardiol
(2011) - et al.
Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension
Int J Cardiol
(2011) - et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)
J Am Coll Cardiol
(2006) - et al.
Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study
Chest
(2000) - et al.
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
Am J Cardiol
(2000) - et al.
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation
J Am Coll Cardiol
(2011) - et al.
Pulmonary arterial hypertension
N Engl J Med
(2004) - et al.
Chronic thromboembolic pulmonary hypertension
Circulation
(2006) - et al.
Predictors of outcome in chronic thromboembolic pulmonary hypertension
Circulation
(2007)
Pulmonary endarterectomy: experience and lessons learned in 1,500 cases
Ann Thorac Surg
Cited by (151)
Hospital Outcomes in Patients With Pulmonary Hypertension With Atrial Fibrillation in the United States
2024, American Journal of CardiologyAnalysis of relationship between P wave dispersion and diagnosis of pulmonary arterial hypertension and risk stratification
2023, Journal of ElectrocardiologyPulmonary hypertension: An unexplored risk factor for stroke in patients with atrial fibrillation
2023, Journal of Stroke and Cerebrovascular DiseasesElectrocardiogram in patients with pulmonary hypertension
2023, Journal of Electrocardiology
- 1
The first two authors contributed equally to this work.